DEALS: Novartis signs two major licensing deals

DEALS

WHO

WITH

WHAT

SCOOP

Novartis

Human Genome Sciences

$552.2M licensing deal

Novartis has licensed HGS's hepatitis C drug Albuferon for an upfront payment of $45 million and milestones of up to $507.5 million for the development of the therapy.

Novartis

Cytopia

$274 licensing deal

Novartis will pay Cytopia $13M in up front fees as part of a $274M package that includes major milestones on new therapies to prevent transplant rejection and to treat auto-immune diseases.

AnGes

Vical

$100M licensing deal

Japan's AnGes has agreed to pay up to $100 million in research funding and milestone fees in a licensing deal for Vical's Allovectin-7 cancer therapy.

BioLineRx

Gevys Pharmaceuticals

Licensing deal

The deal is for worldwide rights to Gevys Pharmaceuticals' experimental pain drug BL-3010.

Novartis

NeuTec Pharma

$569M acquisition

Novartis has bid $569 million to acquire NeuTec Pharma, a British drug developer with several late-stage candidates in the pipeline. NeuTec's board has backed the takeover.

Covance

Signet Laboratories

$8.95M asset acquisition

Covance has acquired most of the assets of Signet Laboratories for $8.95 million.

Biogen Idec

Fumapharm

Acquisition

The companies will continue to collaborate BG-12 for MS and psoriasis and Biogen Idec will expand its European operations.

PerkinElmer

Clinical & Analytical Service Solutions

Acquisition

PerkinElmer has acquired Clinical & Analytical Service Solutions for an undisclosed sum.

Gilead Sciences

Raylo Chemicals

$147.8M buyout

Gilead says it needs Raylo, a subsidiary of Germany's Degussa, for its experience as a chemical and manufacturing experience.

Angiotech Pharmaceuticals

Quill Medical

$40M buyout

Quill Medical makes the Contour Threads surgical suture product.

Bristol-Myers Squibb

Lexicon Genetics

$20M alliance

Bristol-Myers Squibb has extended its alliance with Lexicon Genetics on psychiatry and neurology therapies by two years, adding another $20 million in new research funds.

Parata Systems

McKesson'

Sale

Parata Systems has inked a deal to buy virtually all of the assets in McKesson's automated prescriptions systems division. McKesson becomes Parata's sole third-party distributor in the U.S.

CombinatoRx

Cystic Fibrosis Foundation Therapeutics

$13.8M collaboration

The companies will collaborate to find new drug combination therapies for cystic fibrosis.

Highland Clan

Raptor Pharmaceutical

Reverse takeover

Raptor will become a wholly owned subsidiary of Highland and Highland will focus solely on the development of Raptor's RAP technology.